Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cue Biopharma, Inc.CUE · Entity 6301 | Director | January 02, 2026 | January 06, 2026 |
| OTONOMY, INC.OTIC · Entity 116495 | Director | June 21, 2022 | June 23, 2022 |
| TALPHERA, INC.TLPH · Entity 7102 | Director | June 22, 2026 | June 24, 2026 |
| aTYR PHARMA INCATYR · Entity 7233 | Chief Financial Officer | February 03, 2026 | February 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cue Biopharma, Inc.
Report date January 02, 2026 · Filed January 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.34 · Expires 2036-01-01 | Direct | 24,400 |
Reported balance
After 2026-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 24,400 · Balance 24,400 F1: Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy. F2: This stock option becomes fully exercisable on the first anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy.
F2: This stock option becomes fully exercisable on the first anniversary of the grant date.
OTONOMY, INC.
Report date June 21, 2022 · Filed June 23, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.95 · Expires 2032-06-20 | Direct | 27,500 |
Reported balance
After 2022-06-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-21 · Grant · Acquired 27,500 · Balance 27,500 F1: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date, and (ii) the date of the Issuer's next annual meeting of stockholders occurring after the grant date, provided that the Reporting Person remains a service provider through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date, and (ii) the date of the Issuer's next annual meeting of stockholders occurring after the grant date, provided that the Reporting Person remains a service provider through such date.
TALPHERA, INC.
Report date June 22, 2026 · Filed June 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 13,647 |
Reported balance
After 2026-06-22 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-22 · Grant · Acquired 5,100 · Balance 13,647 F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2: 100% of the restricted stock units shall vest on the first anniversary of the grant date, subject to Reporting Person's continuous service to the Company. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.98 · Expires 2036-06-21 | Direct | 30,700 |
Reported balance
After 2026-06-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-22 · Grant · Acquired 30,700 · Balance 30,700 F3: 100% of the shares subject to the option shall vest on the one-year anniversary of the grant date, subject to the Reporting Person's continuous service to the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F2: 100% of the restricted stock units shall vest on the first anniversary of the grant date, subject to Reporting Person's continuous service to the Company.
F3: 100% of the shares subject to the option shall vest on the one-year anniversary of the grant date, subject to the Reporting Person's continuous service to the Company.
aTYR PHARMA INC
Report date February 03, 2026 · Filed February 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 37,296 |
Ending reported balance
After 2026-02-04 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-02-03 · Exercise / conversion · Acquired 3,750 · Balance 38,854 F1: Represents shares acquired upon the vesting of restricted stock units (RSUs) granted to the Reporting Person on February 3, 2022. F2: Restricted stock units convert into common stock on a one-for-one basis. Row 2 · 2026-02-04 · Sale · Disposed 1,558 · Balance 37,296 F3: Sale made by the Reporting Person to satisfy tax withholding obligations in connection with the partial vesting of RSUs granted on February 3, 2022. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-02-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-02-03 · Exercise / conversion · Disposed 3,750 · Balance 0 F2: Restricted stock units convert into common stock on a one-for-one basis. F4: The RSUs vest in four equal annual installments beginning on February 3, 2023, such that the RSUs fully vest on February 3, 2026. The RSUs are subject to accelerated vesting upon termination without cause upon a change of control of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares acquired upon the vesting of restricted stock units (RSUs) granted to the Reporting Person on February 3, 2022.
F2: Restricted stock units convert into common stock on a one-for-one basis.
F3: Sale made by the Reporting Person to satisfy tax withholding obligations in connection with the partial vesting of RSUs granted on February 3, 2022.
F4: The RSUs vest in four equal annual installments beginning on February 3, 2023, such that the RSUs fully vest on February 3, 2026. The RSUs are subject to accelerated vesting upon termination without cause upon a change of control of the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 22, 2026 Filed Jun 24, 2026 21:10 UTC | TALPHERA, INC. TLPH · Entity 7102 | GrantStock Option (Right to Buy) · Derivative | 30,700 | $0.00 Strike: $0.98 | $0.00 |
DisclosureSEC source: 0001305178-26-000002 · form4-06242026_090654.xml · derivative · entry 2 Broadfoot Jill Marie · CIK 0001305178 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,700 Underlying: Common Stock · 30,700 shares Expires 2036-06-21 F3 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the one-year anniversary of the grant date, subject to the Reporting Person's continuous service to the Company. Read SEC document |
| June 22, 2026 Filed Jun 24, 2026 21:10 UTC | TALPHERA, INC. TLPH · Entity 7102 | GrantCommon Stock | 5,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001305178-26-000002 · form4-06242026_090654.xml · nonDerivative · entry 1 Broadfoot Jill Marie · CIK 0001305178 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,647 F1 · security: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · shares: 100% of the restricted stock units shall vest on the first anniversary of the grant date, subject to Reporting Person's continuous service to the Company. Read SEC document |
| February 04, 2026 Filed Feb 5, 2026 00:15 UTC | aTYR PHARMA INC ATYR · Entity 7233 | SaleCommon Stock | 1,558 | $0.98 | $1,520.61 |
DisclosureSEC source: 0001193125-26-038002 · ownership.xml · nonDerivative · entry 2 Broadfoot Jill Marie · CIK 0001305178 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,296 F3 · kind: Sale made by the Reporting Person to satisfy tax withholding obligations in connection with the partial vesting of RSUs granted on February 3, 2022. Read SEC document |
| February 03, 2026 Filed Feb 5, 2026 00:15 UTC | aTYR PHARMA INC ATYR · Entity 7233 | Exercise / conversionRestricted Stock Unit · Derivative | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-038002 · ownership.xml · derivative · entry 3 Broadfoot Jill Marie · CIK 0001305178 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: The RSUs vest in four equal annual installments beginning on February 3, 2023, such that the RSUs fully vest on February 3, 2026. The RSUs are subject to accelerated vesting upon termination without cause upon a change of control of the Issuer. F4 · derivative.expiration_date: The RSUs vest in four equal annual installments beginning on February 3, 2023, such that the RSUs fully vest on February 3, 2026. The RSUs are subject to accelerated vesting upon termination without cause upon a change of control of the Issuer. Read SEC document |
| February 03, 2026 Filed Feb 5, 2026 00:15 UTC | aTYR PHARMA INC ATYR · Entity 7233 | Exercise / conversionCommon Stock | 3,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-038002 · ownership.xml · nonDerivative · entry 1 Broadfoot Jill Marie · CIK 0001305178 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,854 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares acquired upon the vesting of restricted stock units (RSUs) granted to the Reporting Person on February 3, 2022. F2 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| January 09, 2026 Filed Jan 9, 2026 22:42 UTC | aTYR PHARMA INC ATYR · Entity 7233 | GrantEmployee Stock Option (right to buy) · Derivative | 412,500 | $0.00 Strike: $0.71 | $0.00 |
DisclosureSEC source: 0001193125-26-009156 · ownership.xml · derivative · entry 2 Broadfoot Jill Marie · CIK 0001305178 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 412,500 Underlying: Common Stock · 412,500 shares Expires 2036-01-09 F2 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 36 equal monthly installments beginning February 9, 2026, such that this option will be fully exercisable on January 9, 2029. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:00 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 24,400 | $0.00 Strike: $0.34 | $0.00 |
DisclosureSEC source: 0001193125-26-004358 · ownership.xml · derivative · entry 1 Broadfoot Jill Marie · CIK 0001305178 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,400 Underlying: Common Stock · 24,400 shares Expires 2036-01-01 F1 · shares: Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy. F2 · derivative.exercise_date: This stock option becomes fully exercisable on the first anniversary of the grant date. Read SEC document |
| October 23, 2025 Filed Oct 24, 2025 20:46 UTC | TALPHERA, INC. TLPH · Entity 7102 | GrantStock Option (Right to Buy) · Derivative | 25,600 | $0.00 Strike: $1.14 | $0.00 |
DisclosureSEC source: 0001305178-25-000004 · form4-10242025_081048.xml · derivative · entry 2 Broadfoot Jill Marie · CIK 0001305178 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,600 Underlying: Common Stock · 25,600 shares Expires 2035-10-22 F3 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the one-year anniversary of the grant date, subject to the Reporting Person's continuous service to the Company. Read SEC document |
| October 23, 2025 Filed Oct 24, 2025 20:46 UTC | TALPHERA, INC. TLPH · Entity 7102 | GrantCommon Stock | 4,267 | $0.00 | $0.00 |
DisclosureSEC source: 0001305178-25-000004 · form4-10242025_081048.xml · nonDerivative · entry 1 Broadfoot Jill Marie · CIK 0001305178 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,547 F1 · security: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · shares: 100% of the restricted stock units shall vest on the first anniversary of the grant date, subject to Reporting Person's continuous service to the Company. Read SEC document |
| June 04, 2025 Filed Jun 6, 2025 20:00 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 48,800 | $0.00 Strike: $0.62 | $0.00 |
DisclosureSEC source: 0000950170-25-083026 · ownership.xml · derivative · entry 1 Broadfoot Jill Marie · CIK 0001305178 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,800 Underlying: Common Stock · 48,800 shares Expires 2035-06-03 F1 · shares: Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy. F2 · derivative.exercise_date: This option was granted on June 4, 2025. The shares underlying the option are scheduled to vest over three years with one-third vesting on the one-year anniversary of the grant date and the balance vesting in eight equal quarterly installments. Read SEC document |
| February 04, 2025 Filed Feb 4, 2025 23:14 UTC | aTYR PHARMA INC ATYR · Entity 7233 | SaleCommon Stock | 1,254 | $3.78 | $4,740.12 |
DisclosureSEC source: 0000950170-25-013884 · ownership.xml · nonDerivative · entry 2 Broadfoot Jill Marie · CIK 0001305178 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,763 F4 · kind: Sale made by the Reporting Person to satisfy tax withholding obligations in connection with the partial vesting of RSUs granted on February 3, 2022. Read SEC document |
| February 03, 2025 Filed Feb 4, 2025 23:14 UTC | aTYR PHARMA INC ATYR · Entity 7233 | Exercise / conversionRestricted Stock Unit · Derivative | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-013884 · ownership.xml · derivative · entry 3 Broadfoot Jill Marie · CIK 0001305178 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,750 Underlying: Common Stock · 3,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F5 · derivative.exercise_date: The RSUs vest in four equal annual installments beginning on February 3, 2023, such that the RSUs will fully vest on February 3, 2026. The RSUs are subject to accelerated vesting upon termination without cause upon a change of control of the Issuer. F5 · derivative.expiration_date: The RSUs vest in four equal annual installments beginning on February 3, 2023, such that the RSUs will fully vest on February 3, 2026. The RSUs are subject to accelerated vesting upon termination without cause upon a change of control of the Issuer. Read SEC document |
| February 03, 2025 Filed Feb 4, 2025 23:14 UTC | aTYR PHARMA INC ATYR · Entity 7233 | Exercise / conversionCommon Stock | 3,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-013884 · ownership.xml · nonDerivative · entry 1 Broadfoot Jill Marie · CIK 0001305178 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,017 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares acquired upon the vesting of restricted stock units (RSUs) granted to the Reporting Person on February 3, 2022. F2 · price: Restricted stock units convert into common stock on a one-for-one basis. F3 · balance_after: Includes 1,307 shares acquired on November 15, 2024 under the Company's 2015 Employee Purchase Plan. Read SEC document |
| January 08, 2025 Filed Jan 10, 2025 21:05 UTC | aTYR PHARMA INC ATYR · Entity 7233 | GrantEmployee Stock Option (right to buy) · Derivative | 275,000 | $0.00 Strike: $3.74 | $0.00 |
DisclosureSEC source: 0000950170-25-004145 · ownership.xml · derivative · entry 1 Broadfoot Jill Marie · CIK 0001305178 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Stock · 275,000 shares Expires 2035-01-08 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning February 8, 2025, such that this option will be fully exercisable on January 8, 2029. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer. Read SEC document |
| June 24, 2024 Filed Jun 24, 2024 23:11 UTC | TALPHERA, INC. TLPH · Entity 7102 | GrantStock Option (Right to Buy) · Derivative | 13,044 | $0.00 Strike: $0.89 | $0.00 |
DisclosureSEC source: 0001415889-24-018073 · form4-06242024_110610.xml · derivative · entry 2 Broadfoot Jill Marie · CIK 0001305178 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,044 Underlying: Common Stock · 13,044 shares Expires 2034-06-23 F3 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the one-year anniversary of the grant date, subject to the Reporting Person's continuous service to the Company. Read SEC document |
| June 24, 2024 Filed Jun 24, 2024 23:11 UTC | TALPHERA, INC. TLPH · Entity 7102 | GrantCommon Stock | 2,174 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-018073 · form4-06242024_110610.xml · nonDerivative · entry 1 Broadfoot Jill Marie · CIK 0001305178 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,280 F1 · security: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · shares: 100% of the restricted stock units shall vest on the first anniversary of the grant date, subject to Reporting Person's continuous service to the Company. Read SEC document |
| May 31, 2024 Filed Jun 3, 2024 12:38 UTC | aTYR PHARMA INC LIFE · Entity 7233 | PurchaseCommon Stock | 5,000 | $1.79 | $8,950.00 |
DisclosureSEC source: 0000950170-24-067668 · ownership.xml · nonDerivative · entry 1 Broadfoot Jill Marie · CIK 0001305178 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,960 F1 · balance_after: Includes 2,139 shares acquired on May 15, 2024 under the Company's 2015 Employee Purchase Plan. Read SEC document |
| February 06, 2024 Filed Feb 7, 2024 01:18 UTC | aTYR PHARMA INC LIFE · Entity 7233 | SaleCommon stock | 1,590 | $1.69 | $2,687.10 |
DisclosureSEC source: 0001209191-24-002947 · doc4.xml · nonDerivative · entry 2 Broadfoot Jill Marie · CIK 0001305178 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,821 F3 · kind: Sale made by the Reporting Person to satisfy tax withholding obligations in connection with the partial vesting of RSUs granted on February 3, 2022. Read SEC document |
| February 05, 2024 Filed Feb 7, 2024 01:18 UTC | aTYR PHARMA INC LIFE · Entity 7233 | Exercise / conversionRestricted Stock Unit · Derivative | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-002947 · doc4.xml · derivative · entry 3 Broadfoot Jill Marie · CIK 0001305178 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 3,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: The RSUs vest in four equal annual installments beginning on February 3, 2023, such that the RSUs will fully vest on February 3, 2026. The RSUs are subject to accelerated vesting upon termination without cause upon a change of control of the Issuer. F4 · derivative.expiration_date: The RSUs vest in four equal annual installments beginning on February 3, 2023, such that the RSUs will fully vest on February 3, 2026. The RSUs are subject to accelerated vesting upon termination without cause upon a change of control of the Issuer. Read SEC document |
| February 05, 2024 Filed Feb 7, 2024 01:18 UTC | aTYR PHARMA INC LIFE · Entity 7233 | Exercise / conversionCommon stock | 3,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-24-002947 · doc4.xml · nonDerivative · entry 1 Broadfoot Jill Marie · CIK 0001305178 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,411 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares acquired upon the vesting of restricted stock units (RSUs) granted to the Reporting Person on February 3, 2022. F2 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| January 05, 2024 Filed Jan 10, 2024 00:33 UTC | aTYR PHARMA INC LIFE · Entity 7233 | GrantEmployee Stock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001209191-24-001299 · doc4.xml · derivative · entry 2 Broadfoot Jill Marie · CIK 0001305178 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2034-01-05 F2 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning February 5, 2024, such that this option will be fully exercisable on January 5, 2028. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer. Read SEC document |
| October 10, 2023 Filed Dec 13, 2023 21:23 UTC | TALPHERA, INC. ACRX · Entity 7102 | GrantStock Option (Right to Buy) · Derivative | 3,487 | $0.00 Strike: $0.68 | $0.00 |
DisclosureSEC source: 0001209191-23-058479 · doc4.xml · derivative · entry 2 Broadfoot Jill Marie · CIK 0001305178 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,487 Underlying: Common Stock · 3,487 shares Expires 2033-10-10 F4 · derivative.exercise_date: 100% of the option shares subject to the option shall vest on the first anniversary of the grant date, subject to Reporting Person's continuous service to the Company. Read SEC document |
| October 10, 2023 Filed Dec 13, 2023 21:23 UTC | TALPHERA, INC. ACRX · Entity 7102 | GrantCommon Stock | 581 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-058479 · doc4.xml · nonDerivative · entry 1 Broadfoot Jill Marie · CIK 0001305178 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,106 F1 · security: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · shares: 100% of the restricted stock units shall vest on the first anniversary of the grant date, subject to Reporting Person's continuous service to the Company. F3 · balance_after: Effective on October 25, 2022, the issuer effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 22:04 UTC | aTYR PHARMA INC LIFE · Entity 7233 | GrantEmployee Stock Option (right to buy) · Derivative | 84,023 | $0.00 Strike: $2.20 | $0.00 |
DisclosureSEC source: 0001209191-23-011275 · doc4.xml · derivative · entry 1 Broadfoot Jill Marie · CIK 0001305178 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,023 Underlying: Common Stock · 84,023 shares Expires 2033-02-16 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning March 16, 2023, such that this option will be fully exercisable on February 16, 2027. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer. Read SEC document |
| February 06, 2023 Filed Feb 7, 2023 00:00 UTC | aTYR PHARMA INC LIFE · Entity 7233 | SaleCommon stock | 1,566 | $2.36 | $3,695.76 |
DisclosureSEC source: 0001209191-23-007364 · doc4.xml · nonDerivative · entry 2 Broadfoot Jill Marie · CIK 0001305178 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,460 F4 · kind: Sale made by the Reporting Person to satisfy tax withholding obligations in connection with the partial vesting of RSUs granted on February 3, 2022. Read SEC document |
| February 03, 2023 Filed Feb 7, 2023 00:00 UTC | aTYR PHARMA INC LIFE · Entity 7233 | Exercise / conversionRestricted Stock Unit · Derivative | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-007364 · doc4.xml · derivative · entry 3 Broadfoot Jill Marie · CIK 0001305178 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,250 Underlying: Common Stock · 3,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F5 · derivative.exercise_date: The RSUs vest in four equal annual installments beginning on February 3, 2023, such that the RSUs will fully vest on February 3, 2026. The RSUs are subject to accelerated vesting upon termination without cause upon a change of control of the Issuer. F5 · derivative.expiration_date: The RSUs vest in four equal annual installments beginning on February 3, 2023, such that the RSUs will fully vest on February 3, 2026. The RSUs are subject to accelerated vesting upon termination without cause upon a change of control of the Issuer. Read SEC document |
| February 03, 2023 Filed Feb 7, 2023 00:00 UTC | aTYR PHARMA INC LIFE · Entity 7233 | Exercise / conversionCommon stock | 3,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-007364 · doc4.xml · nonDerivative · entry 1 Broadfoot Jill Marie · CIK 0001305178 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,026 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares acquired upon the vesting of restricted stock units (RSUs) granted to the Reporting Person on February 3, 2022. F2 · price: Restricted stock units convert into common stock on a one-for-one basis. F3 · balance_after: Includes 986 shares acquired under that Company's 2015 Employee Stock Purchase Plan on November 15, 2022. Read SEC document |
| July 15, 2022 Filed Jul 15, 2022 23:35 UTC | TALPHERA, INC. ACRX · Entity 7102 | GrantStock Option (Right to Buy) · Derivative | 31,000 | $0.00 Strike: $0.23 | $0.00 |
DisclosureSEC source: 0001209191-22-042311 · doc4.xml · derivative · entry 2 Broadfoot Jill Marie · CIK 0001305178 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,000 Underlying: Common Stock · 31,000 shares Expires 2032-07-14 F3 · derivative.exercise_date: 100% of the option shares subject to the option shall vest on the first anniversary of the grant date, subject to Reporting Person's continuous service to the Company. Read SEC document |
| July 15, 2022 Filed Jul 15, 2022 23:35 UTC | TALPHERA, INC. ACRX · Entity 7102 | GrantCommon Stock | 15,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-042311 · doc4.xml · nonDerivative · entry 1 Broadfoot Jill Marie · CIK 0001305178 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,500 F1 · security: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · shares: 100% of the restricted stock units shall vest on the first anniversary of the grant date, subject to Reporting Person's continuous service to the Company. Read SEC document |
| June 21, 2022 Filed Jun 23, 2022 16:31 UTC | OTONOMY, INC. OTIC · Entity 116495 | GrantStock Option (right to buy) · Derivative | 27,500 | $0.00 Strike: $1.95 | $0.00 |
DisclosureSEC source: 0001209191-22-038883 · doc4.xml · derivative · entry 1 Broadfoot Jill Marie · CIK 0001305178 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,500 Underlying: Common Stock · 27,500 shares Expires 2032-06-20 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date, and (ii) the date of the Issuer's next annual meeting of stockholders occurring after the grant date, provided that the Reporting Person remains a service provider through such date. Read SEC document |
| May 24, 2022 Filed May 26, 2022 20:32 UTC | aTYR PHARMA INC LIFE · Entity 7233 | GrantEmployee Stock Option (right to buy) · Derivative | 75,347 | $0.00 Strike: $2.81 | $0.00 |
DisclosureSEC source: 0001209191-22-032209 · doc4.xml · derivative · entry 2 Broadfoot Jill Marie · CIK 0001305178 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,347 Underlying: Common Stock · 75,347 shares Expires 2032-05-24 F2 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning June 24, 2022, such that this option will be fully exercisable on May 24, 2026. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer. Read SEC document |
| February 03, 2022 Filed Feb 7, 2022 21:56 UTC | aTYR PHARMA INC LIFE · Entity 7233 | GrantRestricted Stock Units · Derivative | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-007489 · doc4.xml · derivative · entry 2 Broadfoot Jill Marie · CIK 0001305178 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The RSUs are scheduled to vest in four equal annual installments beginning on February 3, 2023, such that the RSUs will fully vest on February 3, 2026. This grant is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer. F3 · derivative.expiration_date: The RSUs are scheduled to vest in four equal annual installments beginning on February 3, 2023, such that the RSUs will fully vest on February 3, 2026. This grant is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer. Read SEC document |
| February 03, 2022 Filed Feb 7, 2022 21:56 UTC | aTYR PHARMA INC LIFE · Entity 7233 | GrantEmployee Stock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $5.52 | $0.00 |
DisclosureSEC source: 0001209191-22-007489 · doc4.xml · derivative · entry 1 Broadfoot Jill Marie · CIK 0001305178 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2032-02-03 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning March 3, 2022, such that this option will be fully exercisable on February 3, 2026. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer. Read SEC document |
| January 13, 2022 Filed Jan 18, 2022 13:39 UTC | aTYR PHARMA INC LIFE · Entity 7233 | PurchaseCommon stock | 1,923 | $6.75 | $12,980.25 |
DisclosureSEC source: 0001209191-22-003419 · doc4.xml · nonDerivative · entry 1 Broadfoot Jill Marie · CIK 0001305178 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,112 F1 · balance_after: Includes 178 shares acquired under the Company's 2015 Employee Stock Purchase Plan on November 15, 2021. Read SEC document |
| November 20, 2021 Filed Nov 23, 2021 22:37 UTC | TALPHERA, INC. ACRX · Entity 7102 | GrantStock Option (Right to Receive) · Derivative | 30,000 | $0.00 Strike: $0.72 | $0.00 |
DisclosureSEC source: 0001209191-21-066559 · doc4.xml · derivative · entry 2 Broadfoot Jill Marie · CIK 0001305178 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2031-11-19 F3 · derivative.exercise_date: The shares subject to the option vest as follows: 1/3rd of the shares subject to the option vest on the one-year anniversary of the date of grant and the remaining shares subject to the option vest on an equal monthly basis over the following 24 months. Read SEC document |
| November 20, 2021 Filed Nov 23, 2021 22:37 UTC | TALPHERA, INC. ACRX · Entity 7102 | GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-066559 · doc4.xml · nonDerivative · entry 1 Broadfoot Jill Marie · CIK 0001305178 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 F1 · security: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · shares: The restricted stock units shall vest in three equal consecutive annual installments on November 20, 2022, November 20, 2023 and November 20, 2024. Read SEC document |
| August 18, 2021 Filed Aug 20, 2021 18:36 UTC | OTONOMY, INC. OTIC · Entity 116495 | GrantStock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $1.42 | $0.00 |
DisclosureSEC source: 0001209191-21-052839 · doc4.xml · derivative · entry 1 Broadfoot Jill Marie · CIK 0001305178 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2031-08-18 F1 · derivative.exercise_date: 1/3 of the shares subject to the option shall vest upon each anniversary of the grant date, provided that the Reporting Person remains a service provider through each applicable vesting date. Read SEC document |
| May 21, 2021 Filed May 26, 2021 01:04 UTC | aTYR PHARMA INC LIFE · Entity 7233 | GrantEmployee Stock Option (Right to buy) · Derivative | 54,000 | $0.00 Strike: $4.45 | $0.00 |
DisclosureSEC source: 0001209191-21-035833 · doc4.xml · derivative · entry 2 Broadfoot Jill Marie · CIK 0001305178 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,000 Underlying: Common Stock · 54,000 shares Expires 2025-05-21 F2 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning June 21, 2021, such that this option will be fully exercisable on May 21, 2025. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer. Read SEC document |
| February 09, 2021 Filed Feb 10, 2021 02:15 UTC | aTYR PHARMA INC LIFE · Entity 7233 | SaleCommon stock | 390 | $7.66 | $2,987.40 |
DisclosureSEC source: 0001209191-21-009113 · doc4.xml · nonDerivative · entry 2 Broadfoot Jill Marie · CIK 0001305178 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,833 F4 · kind: Sale made by the Reporting Person to satisfy tax withholding obligations in connection with the partial vesting of RSUs granted on February 6, 2019. Read SEC document |
| February 06, 2021 Filed Feb 10, 2021 02:15 UTC | aTYR PHARMA INC LIFE · Entity 7233 | Exercise / conversionRestricted Stock Unit · Derivative | 892 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-009113 · doc4.xml · derivative · entry 3 Broadfoot Jill Marie · CIK 0001305178 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 892 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F5 · derivative.exercise_date: The RSU grant vests as to one-half (1/2) of the total number of units on each one year anniversary of the grant commencing on February 6, 2020. F5 · derivative.expiration_date: The RSU grant vests as to one-half (1/2) of the total number of units on each one year anniversary of the grant commencing on February 6, 2020. Read SEC document |
| February 06, 2021 Filed Feb 10, 2021 02:15 UTC | aTYR PHARMA INC LIFE · Entity 7233 | Exercise / conversionCommon stock | 892 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-009113 · doc4.xml · nonDerivative · entry 1 Broadfoot Jill Marie · CIK 0001305178 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,223 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares acquired upon the vesting of restricted stock units (RSUs) granted to the Reporting Person on February 6, 2019. F2 · price: Restricted stock units convert into common stock on a one-for-one basis. F3 · balance_after: Includes 178 shares acquired under that Company's 2015 Employee Stock Purchase Plan on November 16, 2020. Read SEC document |
| February 04, 2021 Filed Feb 9, 2021 01:08 UTC | aTYR PHARMA INC LIFE · Entity 7233 | GrantEmployee Stock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $4.52 | $0.00 |
DisclosureSEC source: 0001209191-21-008628 · doc4.xml · derivative · entry 1 Broadfoot Jill Marie · CIK 0001305178 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-02-04 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning March 4, 2021, such that this option will be fully exercisable on February 4, 2025. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer. Read SEC document |
| June 19, 2020 Filed Jun 23, 2020 20:27 UTC | aTYR PHARMA INC LIFE · Entity 7233 | PurchaseCommon Stock | 1,850 | $4.22 | $7,807.00 |
DisclosureSEC source: 0001209191-20-038468 · doc4.xml · nonDerivative · entry 1 Broadfoot Jill Marie · CIK 0001305178 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,153 F1 · price: Represents weighted average price for the shares. The shares were purchased at price ranging from $4.21 to $4.24 per share. The reporting person will provide to the Securities and Exchange Commission staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price. Read SEC document |
| May 26, 2020 Filed May 29, 2020 00:22 UTC | aTYR PHARMA INC LIFE · Entity 7233 | GrantEmployee Stock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $4.06 | $0.00 |
DisclosureSEC source: 0001209191-20-032784 · doc4.xml · derivative · entry 2 Broadfoot Jill Marie · CIK 0001305178 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2030-05-26 F2 · derivative.exercise_date: 50% of the shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning June 26, 2020, such that these shares will be fully exercisable on May 26, 2024; 25% of the shares subject to this option will vest on May 26, 2021 if and only if a clinical development milestone is achieved by September 30, 2020; and the remaining 25% of the shares will vest on May 26, 2021 if and only if an additional clinical development milestone is achieved by September 30, 2020. Read SEC document |
| February 07, 2020 Filed Feb 8, 2020 00:30 UTC | aTYR PHARMA INC LIFE · Entity 7233 | SaleCommon stock | 375 | $4.03 | $1,511.25 |
DisclosureSEC source: 0001209191-20-007710 · doc4.xml · nonDerivative · entry 2 Broadfoot Jill Marie · CIK 0001305178 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,125 F4 · kind: Sale made by the Reporting Person to satisfy tax withholding obligations in connection with the partial vesting of RSUs granted on February 6, 2019. Read SEC document |
| February 06, 2020 Filed Feb 8, 2020 00:30 UTC | aTYR PHARMA INC LIFE · Entity 7233 | Exercise / conversionRestricted Stock Unit · Derivative | 893 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-007710 · doc4.xml · derivative · entry 4 Broadfoot Jill Marie · CIK 0001305178 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 893 Underlying: Common Stock · 893 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F6 · derivative.exercise_date: The RSU grant vests as to one-half (1/2) of the total number of units on each one year anniversary of the grant commencing on February 6, 2020. F6 · derivative.expiration_date: The RSU grant vests as to one-half (1/2) of the total number of units on each one year anniversary of the grant commencing on February 6, 2020. Read SEC document |
| February 06, 2020 Filed Feb 8, 2020 00:30 UTC | aTYR PHARMA INC LIFE · Entity 7233 | Exercise / conversionCommon stock | 893 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-007710 · doc4.xml · nonDerivative · entry 1 Broadfoot Jill Marie · CIK 0001305178 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares acquired upon the vesting of restricted stock units (RSUs) granted to the Reporting Person on February 6, 2019. F2 · price: Restricted stock units convert into common stock on a one-for-one basis. F3 · balance_after: Includes 718 shares acquired under that Company's 2015 Employee Stock Purchase Plan on November 16, 2019. Read SEC document |
| February 05, 2020 Filed Feb 8, 2020 00:30 UTC | aTYR PHARMA INC LIFE · Entity 7233 | GrantEmployee Stock Option (right to buy) · Derivative | 23,359 | $0.00 Strike: $4.39 | $0.00 |
DisclosureSEC source: 0001209191-20-007710 · doc4.xml · derivative · entry 3 Broadfoot Jill Marie · CIK 0001305178 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,359 Underlying: Common Stock · 23,359 shares Expires 2030-02-05 F5 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning March 5, 2020, such that this option will be fully exercisable on February 5, 2024. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer. Read SEC document |
| February 06, 2019 Filed Feb 9, 2019 00:16 UTC | aTYR PHARMA INC LIFE · Entity 7233 | GrantRestricted Stock Unit · Derivative | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-008757 · doc4.xml · derivative · entry 2 Broadfoot Jill Marie · CIK 0001305178 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The RSUs are scheduled to vest in two equal annual installments beginning on February 6, 2020, such that the RSUs will fully vest on February 6, 2021. This grant is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer. F3 · derivative.expiration_date: The RSUs are scheduled to vest in two equal annual installments beginning on February 6, 2020, such that the RSUs will fully vest on February 6, 2021. This grant is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer. Read SEC document |
| February 06, 2019 Filed Feb 9, 2019 00:16 UTC | aTYR PHARMA INC LIFE · Entity 7233 | GrantEmployee Stock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.52 | $0.00 |
DisclosureSEC source: 0001209191-19-008757 · doc4.xml · derivative · entry 1 Broadfoot Jill Marie · CIK 0001305178 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2029-02-06 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning March 6, 2019, such that this option will be fully exercisable on February 6, 2023. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.